Table 5.
Outcomes versus treatment in 30 crystalline LCPT patients
| Characteristic | SCT+Chemotherapy (n=10) | Chemotherapy Alone (n=12) | None (n=8) | P Value |
|---|---|---|---|---|
| Median age (range), yr | 51 (39–59) | 67.5 (47–85) | 65 (47–87) | 0.001 |
| SCT versus chemotherapy 0.002 | ||||
| SCT versus none 0.003 | ||||
| Chemotherapy versus none 0.79 | ||||
| MM | 6 | 3 | 1 | 0.05 |
| SCT versus chemotherapy 0.07 | ||||
| SCT versus none 0.07 | ||||
| Chemotherapy versus none >.99 | ||||
| Smoldering MM | 1 | 1 | 4 | 0.06 |
| MGRS | 3 | 6 | 3 | 0.65 |
| Other HLN | 0 | 2 | 0 | 0.10 |
| eGFR (initial)a | 48.8 (49.8) | 30.0 (32.0) | 34.8 (37.9) | 0.19 |
| SCT versus chemotherapy 0.09 | ||||
| SCT versus none 0.25 | ||||
| Chemotherapy versus none 0.52 | ||||
| sCr, mg/dl (initial)a | 2.01 (1.55) | 2.48 (2.15) | 2.38 (1.85) | 0.48 |
| Proteinuria (initial), g/24 ha | 3.05 (1.41) | 2.95 (2.95) | 2.15 (1.89) | 0.01 |
| SCT versus chemotherapy 0.01 | ||||
| SCT versus none >.99 | ||||
| Chemotherapy versus none 0.03 | ||||
| Follow-up monthsa | 65.2 (57.5) | 40.5 (32.0) | 59.0 (48.5) | 0.60 |
| eGFR (final)ab | 58.9 (51.5) | 31.0 (27.8) | 27.9 (33.5) | 0.01 |
| SCT versus chemotherapy 0.01 | ||||
| SCT versus none 0.01 | ||||
| Chemotherapy versus none 0.94 | ||||
| eGFR<60 (final)ab | 7/10 | 12/12 | 7/7 | 0.32 |
| Change in eGFR | +10.1 (+7.6) | +1.0 (-4.5) | −6.9 (-4.9) | 0.04 |
| SCT versus chemotherapy 0.16 | ||||
| SCT versus none 0.06 | ||||
| Chemotherapy versus none 0.57 | ||||
| sCr (final), mg/dlab | 1.43 (1.45) | 2.27 (2.07) | 3.11 (1.75) | 0.05 |
| SCT versus chemotherapy 0.03 | ||||
| SCT versus none 0.07 | ||||
| Chemotherapy versus none 0.87 | ||||
| Proteinuria (final), g/24 hab | 0.85 (0.80) | 1.56 (1.59) | 1.96 (1.92) | 0.05 |
| SCT versus chemotherapy 0.15 | ||||
| SCT versus none 0.02 | ||||
| Chemotherapy versus none 0.39 | ||||
| Hematologic outcomes | 0.12 | |||
| CR | 2/10 | 3/12 | 0/8 | 0.39 |
| VGPR | 1/10 | 0/12 | 0/8 | 0.62 |
| PR | 2/10 | 0/12 | 1/8 | 0.35 |
| Stable disease | 5/10 | 9/12 | 7/8 | 0.24 |
| Renal functional outcomesbc | 0.07 | |||
| SCT versus chemotherapy 0.16 | ||||
| SCT versus none 0.12 | ||||
| Chemotherapy versus none 0.66 | ||||
| Improved | 4/10 | 3/12 | 1/7 | |
| Stable | 6/10 | 5/12 | 4/7 | |
| Worsening CKD | 0/10 | 4/12 | 0/7 | |
| ESRD | 0/10 | 0/12 | 2/7 | |
| Death | 0/10 | 4/12 | 3/8 | 0.12 |
SCr, serum creatinine.
a
Values are mean (median).
b
One untreated patient had no renal follow-up data.
c
Improved: ΔSCr>–0.5 mg/dl; stable: ΔSCr±0.5 mg/dl from baseline; worsening: ΔSCr>0.5 mg/dl.